ARTICLE | Company News
Hope Medicine in-licenses Bayer’s BAY 1158061
April 11, 2019 8:53 PM UTC
Hope Medicine gained exclusive, worldwide rights from Bayer to develop and commercialize BAY 1158061 to treat male and female pattern hair loss, endometriosis and other chronic diseases with dysregulated PRL signaling. Hope Medicine Inc. (Beijing, China) also raised a $26 million series A round to support clinical development of the human antibody targeting PRLR.
Bayer AG (Xetra:BAYN) will receive an undisclosed upfront payment and is eligible for undisclosed development and commercialization milestones, plus tiered royalties...
BCIQ Company Profiles